^
Association details:
| Biomarker: | HRAS G13R |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | MK-2206 (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
Excerpt:
We examined the effects of MK2206 on thyroid cancer cells with respect to the genotypes of the PI3K/Akt pathway....The SW1736 cell, lacking mutations in the PI3K/Akt pathway, had minimal response to MK2206, but transfection with exogenous PIK3CA mutants, PIK3CA H1047R and E545K, significantly increased its sensitivity to MK2206....Genotypes of thyroid cell lines and their sensitivities to MK2206.
DOI:
10.1210/jc.2010-2644
